Pfizer Inc. $PFE Shares Purchased by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp increased its position in shares of Pfizer Inc. (NYSE:PFE) by 10.2% in the 2nd quarter, Holdings Channel reports. The firm owned 3,137,191 shares of the biopharmaceutical company’s stock after purchasing an additional 289,590 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Pfizer were worth $75,544,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in PFE. Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the fourth quarter worth about $26,000. Keb Asset Management LLC purchased a new stake in Pfizer during the 2nd quarter valued at about $26,000. HFM Investment Advisors LLC raised its holdings in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Global Trust Asset Management LLC raised its holdings in Pfizer by 126.7% in the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 650 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer shares benefited from renewed enthusiasm for cancer vaccines after Merck and Moderna reported positive melanoma-trial results for their personalized mRNA vaccine and Keytruda combination. The news has encouraged investors to reassess Pfizer’s own cancer-vaccine ambitions and broader mRNA exposure. Pfizer Stock Rises Wednesday: What’s Going On?
• Positive Sentiment: Pfizer’s obesity strategy remains a potential long-term catalyst. Investors are watching berobenatide, a possible monthly treatment intended to compete with leading GLP-1 drugs and help diversify revenue beyond legacy products. Pfizer’s Obesity Push
• Positive Sentiment: Pfizer’s high dividend yield and recent share performance are attracting income-oriented investors. Recent filings also indicate substantial hedge-fund buying, while unusually heavy call-option activity points to improving speculative sentiment. Yield Hunters and Hedge-Fund Buying
• Neutral Sentiment: Pfizer completed a real-world study evaluating Ibrance in advanced breast cancer. The study’s completion could provide useful evidence for the product, but investors are awaiting the data and any commercial implications. Pfizer’s Ibrance Study Update
• Negative Sentiment: Pfizer is settling thousands of Depo-Provera lawsuits alleging a link to intracranial meningiomas. While a settlement program may reduce litigation uncertainty, it also highlights potentially significant financial exposure and keeps legal risk overhanging the stock. Why Is Pfizer Settling Thousands of Legal Claims?
• Negative Sentiment: Investors remain focused on Pfizer’s patent cliff. New and acquired medicines may replace much of the revenue lost as older patents expire, but the transition leaves limited room for execution errors and raises concerns about longer-term growth. Pfizer Stock Is a Race Between New Drugs and Old Patents
• Negative Sentiment: Merck’s deeper investment in personalized cancer vaccines raises the competitive bar for Pfizer and could make it harder for Pfizer to establish a leading position in this emerging market. Merck Raises the Stakes for Pfizer’s Cancer Vaccine Ambitions

Pfizer Stock Down 1.5%

PFE stock opened at $27.83 on Friday. The firm has a market cap of $158.62 billion, a PE ratio of 36.62 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The firm’s 50 day moving average price is $25.27 and its 200-day moving average price is $26.24. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. Pfizer’s dividend payout ratio is currently 226.32%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PFE. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Citigroup increased their price target on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. lowered their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Weiss Ratings cut Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday. Finally, HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and cut their target price for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.